What is BioDot?
Founded in 1994 and headquartered in Irvine, California, BioDot specializes in the design and manufacture of automated ultralow volume fluid dispensing systems. The company serves as a cornerstone for laboratories and industrial manufacturers requiring high-accuracy liquid handling. Its core competencies include advanced cell printing, fluid aspiration, and the development of specialized support systems for lateral flow assays and microarray production. By bridging the gap between complex fluid dynamics and scalable manufacturing, BioDot enables its clients to achieve high-throughput precision in sensitive diagnostic environments, maintaining a competitive edge through decades of technical refinement and domain expertise.
How much funding has BioDot raised?
BioDot has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in BioDot
PPP
Public-Private Partnership
What's next for BioDot?
With the successful closure of this late-stage financing, BioDot is well-positioned to accelerate its strategic roadmap. The company is expected to focus on scaling its automated dispensing platforms to meet the rising global demand for rapid diagnostic testing and personalized medicine infrastructure. Future growth initiatives will likely prioritize the integration of next-generation sensor technology into its existing product lines, further enhancing the precision of its dispensing systems. As the company navigates this mature phase of its lifecycle, the focus remains on operational efficiency and expanding its footprint in emerging biotech markets, ensuring that its proprietary technology remains the industry standard for high-volume, low-variance fluid management.
See full BioDot company page
